Literature DB >> 11165690

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control.

C E Tan1, L S Chew, L F Chio, E S Tai, H S Lim, S C Lim, L Jayakumar, H K Eng, C J Packard.   

Abstract

OBJECTIVES: To compare cardiovascular risk factors and LDL particle size in well-controlled Type 2 diabetes mellitus and normal subjects.
METHODS: Ninety-three Type 2 diabetic males and 186 age-matched, male controls were studied. Glycaemic control was stable for at least 3 months prior to recruitment. None were on insulin or lipid lowering therapy. Anthropometric indices, blood pressure, lipids, glucose, insulin, apolipoprotein A1 and B, LDL subfraction by density ultracentrifugation were obtained after an overnight fast of 10 h.
RESULTS: Diabetic subjects (mean HbA(1c) 6.6%+/-0.10) did not differ from controls in total cholesterol levels (5.04+/-0.08 vs. 5.16+/-0.05 mmol/l, respectively) but had lower serum HDL cholesterol (0.98+/-0.03 vs. 1.12+/-0.02 mmol/l, P<0.001), higher serum triglyceride (2.38+/-0.16 vs. 1.80+/-0.08 mmol/l, P<0.001), lower LDL(1) and LDL(2) and higher LDL(3) concentration. An LDL(3) concentration exceeding 100 mg/dl was found in 59.1% of diabetics and 39.1% of non-diabetics (P<0.001). Diabetic subjects also had higher body mass index, waist to hip ratio and insulin resistance (HOMA). Difference in LDL subfraction between groups disappeared after adjustments were made for either triglyceride or HDL cholesterol.
CONCLUSION: Well controlled Type 2 diabetes mellitus subjects exhibit an increased cardiovascular burden through low HDL cholesterol and predominance of small, dense LDL particles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165690     DOI: 10.1016/s0168-8227(00)00211-4

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  8 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

Review 2.  Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.

Authors:  Barbara E Stähli; Catherine Gebhard; Jean-Claude Tardif
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

3.  Are Additional Lipid Measures Useful?

Authors:  Ryan D Bradley; Erica B Oberg
Journal:  Integr Med (Encinitas)       Date:  2008-12

Review 4.  Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications.

Authors:  Gianluca Bardini; Carlo M Rotella; Stefano Giannini
Journal:  Rev Diabet Stud       Date:  2012-11-15

5.  Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.

Authors:  Naila Rabbani; Lisa Godfrey; Mingzhan Xue; Fozia Shaheen; Michèle Geoffrion; Ross Milne; Paul J Thornalley
Journal:  Diabetes       Date:  2011-05-26       Impact factor: 9.461

6.  Elevation of small, dense low density lipoprotein cholesterol-a possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos, North-Central Nigeria.

Authors:  Kenneth O Inaku; Obasola O Ogunkeye; Fayeofori M Abbiyesuku; Evelyn K Chuhwak; Christian O Isichei; Lucius C Imoh; Noel O Amadu; Alexander O Abu
Journal:  BMC Clin Pathol       Date:  2017-12-06

7.  Prevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease.

Authors:  S V Madhu; M Aslam; A J Aiman; A Siddiqui; S Dwivedi
Journal:  Indian J Endocrinol Metab       Date:  2017 Jan-Feb

Review 8.  Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials.

Authors:  Minhua Fan; Yuelan Li; Shihong Zhang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.